Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 819)
eröffnet am 24.06.15 16:59:24 von
neuester Beitrag 02.05.24 10:29:26 von
neuester Beitrag 02.05.24 10:29:26 von
Beiträge: 8.522
ID: 1.214.676
ID: 1.214.676
Aufrufe heute: 108
Gesamt: 1.077.259
Gesamt: 1.077.259
Aktive User: 5
ISIN: CA81732W1041 · WKN: A0LBCR · Symbol: PSH
0,3000
EUR
+3,99 %
+0,0115 EUR
Letzter Kurs 10:54:38 L&S Exchange
Neuigkeiten
30.04.24 · Shareribs Anzeige |
26.04.24 · Shareribs Anzeige |
25.04.24 · IRW Press |
24.04.24 · Shareribs Anzeige |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,9700 | +324,79 | |
| 0,8100 | +305,00 | |
| 0,7400 | +36,63 | |
| 6,4000 | +24,51 | |
| 110,70 | +22,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5350 | -17,05 | |
| 0,5300 | -17,19 | |
| 0,6550 | -17,87 | |
| 10,120 | -34,75 | |
| 1,8819 | -55,93 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 58.227.567 von Ghost-Cash am 16.07.18 21:46:48Leider reicht mein spielgeld nicht, hab ja noch andere aktien. Aber ich denke du wirst das verdreissigfachen, wenn du vorher nicht aussteigst😁
Antwort auf Beitrag Nr.: 58.225.413 von Takado am 16.07.18 17:05:13Bin jetzt mit 90´000 Stücken auch dabei. Für mich eine reine Spekulation, vergleichbar mit einer Optionenwette ohne Laufzeitbegrenzung. Die Überzeichnung hat in mir das Interesse erweckt, mal schauen wohin die Reise geht.
Antwort auf Beitrag Nr.: 58.224.735 von techinvestor69 am 16.07.18 15:59:40Erst schreien alle nach investoren. Dann kommen die und der kurs fällt wegen vermeintlicher verwässerung. Was bei dem produkt ein witz ist. Bei Erfolg milliarden umsätze
Sernova Announces $2,000,000 First Closing of Private Placement
Due to Oversubscription, Offering Increased to $2,700,000
LONDON, Ontario, July 16, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) is pleased to announce that it closed $2,000,000 of its non-brokered private placement announced on June 26, 2018. In addition, as the Company has received over-subscriptions of $404,000, it is increasing the total amount of the non-brokered private placement offering of up to $2,700,000 for a total offering of 10,800,000 Special Warrants at $0.25 per Special Warrant. The Company plans to close the balance of the placement on July 20, 2018.
“We are pleased with the strong support from our longstanding as well as new investors including one of Canada’s most prestigious institutional funds who enthusiastically led this placement,” said Dr. Philip Toleikis, President and CEO of Sernova Corp. “We believe Sernova is the first in world to demonstrate survival and vascularization of human islets in a patented, implantable prevascularized device in our first assessment in humans and we are thrilled with our outstanding next-step clinical development program initiated at the University of Chicago for which this funding is primarily focussed.”
Net proceeds from the private placement will be used to support funding of Sernova's FDA cleared US Phase I/II regenerative medicine clinical trial and to advance corporate/academic collaborations utilizing the Company’s platform technology to treat diabetes, hemophilia and other serious disease conditions, as well as for general corporate purposes.
In the first closing on July 13, 2018, Sernova issued 8,000,000 Special Warrants at $0.25 per Special Warrant for gross proceeds of $2,000,000. Each Special Warrant will convert, for no additional consideration, into one Unit (“Unit”) on the earlier of the third business day after a receipt of a final prospectus qualifying the conversion is issued and the day after the expiry of the four-month statutory hold period. Each Unit will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50 per share.
Also, in respect of the first closing, the Company compensated finders by way of cash fees of $35,875 and 143,000 non-transferable finder warrants, each such finder Warrant will be exercisable into one share at $0.35 per share for a period of 24 months. The Company may also compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof.
...
Quelle: www.stockwatch.com
Due to Oversubscription, Offering Increased to $2,700,000
LONDON, Ontario, July 16, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) is pleased to announce that it closed $2,000,000 of its non-brokered private placement announced on June 26, 2018. In addition, as the Company has received over-subscriptions of $404,000, it is increasing the total amount of the non-brokered private placement offering of up to $2,700,000 for a total offering of 10,800,000 Special Warrants at $0.25 per Special Warrant. The Company plans to close the balance of the placement on July 20, 2018.
“We are pleased with the strong support from our longstanding as well as new investors including one of Canada’s most prestigious institutional funds who enthusiastically led this placement,” said Dr. Philip Toleikis, President and CEO of Sernova Corp. “We believe Sernova is the first in world to demonstrate survival and vascularization of human islets in a patented, implantable prevascularized device in our first assessment in humans and we are thrilled with our outstanding next-step clinical development program initiated at the University of Chicago for which this funding is primarily focussed.”
Net proceeds from the private placement will be used to support funding of Sernova's FDA cleared US Phase I/II regenerative medicine clinical trial and to advance corporate/academic collaborations utilizing the Company’s platform technology to treat diabetes, hemophilia and other serious disease conditions, as well as for general corporate purposes.
In the first closing on July 13, 2018, Sernova issued 8,000,000 Special Warrants at $0.25 per Special Warrant for gross proceeds of $2,000,000. Each Special Warrant will convert, for no additional consideration, into one Unit (“Unit”) on the earlier of the third business day after a receipt of a final prospectus qualifying the conversion is issued and the day after the expiry of the four-month statutory hold period. Each Unit will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50 per share.
Also, in respect of the first closing, the Company compensated finders by way of cash fees of $35,875 and 143,000 non-transferable finder warrants, each such finder Warrant will be exercisable into one share at $0.35 per share for a period of 24 months. The Company may also compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof.
...
Quelle: www.stockwatch.com
Trading Spotlight
Antwort auf Beitrag Nr.: 58.209.323 von Takado am 13.07.18 17:15:05Spread in Kanada ist ein halber Cent
Bid und ask sind immer mind. 3 cent unterschied ich komm nicht zum nachkaufen
Ich bleib dabei, dass wir das Tief gesehen haben.
RT 0,23
RT 0,23
Antwort auf Beitrag Nr.: 58.192.754 von sneakee am 12.07.18 00:36:21Das kannst Du sagen, wenn Kurs unter 0,20 gehen sollte...
Antwort auf Beitrag Nr.: 58.167.017 von techinvestor69 am 09.07.18 09:31:21da liegst aber falsch...0.21-0.02 (-8.70%)
Durchsuchen
